Skip to main content
Caplight Logo









ImmunoACT

ImmunoACT

Private
Navi MumbaiHealthcare & Life Scienceshttps://immunoact.com/

Last Round

Series B

May 31, 2023

Est. Valuation

$133.61M

Total Funding Raised

$19.99M

Company Overview

ImmunoACT is a biotechnology company that develops and commercializes affordable CAR-T cell therapies for the treatment of various blood cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

CAR-T cell therapyNexCAR19chimeric antigen receptorcell therapyoncologyB-cell lymphomaleukemia treatmentpersonalized medicinebiotechnologyCD19-targeted therapyclinical-stage biotechliving drugscancer immunotherapycell manufacturinggene therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ImmunoACT Comparables

Compare ImmunoACT with similar companies based on industry and business-model similarity.

ImmunoACT comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Immuneel Therapeutics
92%
Cellogen Therapeutics
82%
JW Therapeutics
77%

ImmunoACT Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 31, 2023
Series ANov 19, 2021
GrantMar 8, 2019

Key People

Founding team and executive leadership

CA RAJAT MAHESHWARI

Chief Financial Officer

Executive Team

ImmunoACT Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 1, 2025

    Presented NexCAR19 CAR-T therapy at ESTIC 2025.

  • Feb 1, 2025

    Launched NexCAR19, India's first indigenous CAR-T therapy.

ImmunoACT Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ImmunoACT Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ImmunoACT's valuation, stock price, and market status.

Firmographic Details

HeadquartersNavi Mumbai
Employee Range196
Year Founded2018
Last FundingMay 31, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?